

Contents

Preface — v

List of contributing authors — vii

1 Angiotensin converting enzyme — 1

Joe M. El-Khoury, Edmunds Reineks and Sihe Wang

- 1.1 Case studies — 1
 - 1.1.1 Patient A — 1
 - 1.1.2 Patient B — 1
 - 1.1.3 Patient C — 2
- 1.2 Biochemistry and physiology — 3
 - 1.2.1 Physiological function — 3
 - 1.2.2 Biochemistry and molecular forms — 3
 - 1.2.3 Tissue sources — 5
 - 1.2.4 Reference ranges — 5
- 1.3 Chemical pathology — 7
 - 1.3.1 ACE in sarcoidosis — 7
- 1.4 Analysis — 9
 - 1.4.1 Specimen — 9
 - 1.4.2 Spectrophotometric methods — 10
 - 1.4.3 High-performance liquid chromatography — 10
 - 1.4.4 Fluorometric methods — 11
 - 1.4.5 Radioassays — 11
 - 1.4.6 Other methods — 11
 - 1.4.7 Inhibitors of ACE — 12
- 1.5 Questions and answers — 12
 - References — 13

2 Acetylcholinesterase and butyrylcholinesterase — 19

Peter L. Platteborze

- 2.1 Case studies — 19
 - 2.1.1 Patient A — 19
 - 2.1.2 Patient B — 20
 - 2.1.3 Patient C — 21
 - 2.1.4 Patient D — 22
 - 2.1.5 Patient E — 22
- 2.2 Biochemistry and physiology of the cholinesterases — 23
 - 2.2.1 Molecular forms — 23
 - 2.2.2 Inheritance of BChE variants — 26
- 2.3 Chemical pathology — 29

- 2.3.1 Pesticide and nerve agent poisoning — 29
- 2.4 Analytical measurements of AChE and BChE — 36
- 2.4.1 Desired specimens — 36
- 2.5 Questions and answers — 38
- References — 40

3 Aldolase — 41

Edmunds Reineks, Joe M. El-Khoury and Sihe Wang

- 3.1 Case studies — 41
- 3.1.1 Patient A — 41
- 3.1.2 Patient B — 42
- 3.1.3 Patient C — 43
- 3.2 Biochemistry and physiology — 43
- 3.2.1 Physiological function — 43
- 3.2.2 Biochemistry and molecular structure — 44
- 3.2.3 Tissue source(s) and expression of ALD — 45
- 3.2.4 Clearance and metabolism of ALD — 45
- 3.2.5 Reference ranges — 46
- 3.3 Chemical pathology — 47
- 3.3.1 Polymyositis/dermatomyositis — 47
- 3.3.2 Duchenne muscular dystrophy — 48
- 3.3.3 Drug-induced myopathy — 48
- 3.3.4 Pathologies in which CK does not reflect the extent of muscle damage — 49
- 3.4 Analysis — 50
- 3.4.1 Specimen — 50
- 3.4.2 Analyte stability — 51
- 3.4.3 Interferences — 51
- 3.4.4 Reference methods — 51
- 3.5 Questions and answers — 52
- References — 53

4 Alkaline phosphatase — 57

Amy E. Schmidt

- 4.1 Case studies — 57
- 4.1.1 Patient A — 57
- 4.1.2 Patient B — 58
- 4.1.3 Patient C — 59
- 4.1.4 Patient D — 60
- 4.1.5 Patient E — 60
- 4.1.6 Patient F — 61

4.2	Biochemistry and physiology — 63
4.2.1	Structure — 63
4.2.2	Physiological function of ALP in tissue/blood/other fluids — 66
4.2.3	Tissue sources of ALP — 66
4.2.4	Clearance/metabolism of enzyme — 67
4.2.5	Reference ranges — 67
4.3	Chemical pathology — 68
4.3.1	Liver disease — 68
4.3.2	Bone disease — 69
4.3.3	Metastatic cancer — 69
4.3.4	Miscellaneous pancreatic disorders — 69
4.3.5	Cystic fibrosis — 70
4.3.6	Chronic renal failure — 70
4.3.7	Drug therapy — 70
4.3.8	Miscellaneous — 71
4.4	Analysis — 71
4.4.1	Technical problems — 71
4.4.2	Reference method — 72
4.4.3	Isoenzyme analysis — 72
4.5	Questions and answers — 75
	Acknowledgements — 75
	References — 76

5 Aspartate aminotransferase and alanine aminotransferase — 81

Joe M. El-Khoury and Sihe Wang

5.1	Case studies — 81
5.1.1	Patient A — 81
5.1.2	Patient B — 82
5.1.3	Patient C — 82
5.1.4	Patient D — 83
5.1.5	Patient E — 84
5.2	Biochemistry and physiology — 84
5.2.1	Molecular forms — 84
5.2.2	Biochemical function — 86
5.2.3	Normal physiology — 86
5.2.4	Reference ranges — 88
5.3	Chemical pathology — 89
5.3.1	Liver disease — 89
5.3.2	Hemochromatosis — 92
5.3.3	Skeletal muscle disease — 93
5.3.4	Heart disease — 94
5.3.5	Other causes of AST increase — 95

5.4	Analysis — 95
5.4.1	Specimens — 95
5.4.2	Reaction used — 95
5.4.3	Interferences — 96
5.4.4	Methods for AST isoenzymes — 97
5.5	Questions and answers — 97
	References — 98
6	Creatine kinase, isoenzymes, and isoforms — 105
	Alan H.B. Wu
6.1	Case studies — 105
6.1.1	Patient A — 105
6.1.2	Patient B — 106
6.1.3	Patient C — 107
6.1.4	Patient D — 108
6.1.5	Patient E — 109
6.2	Biochemistry and physiology — 110
6.2.1	Molecular forms — 110
6.2.2	CK isoenzymes, atypical forms, and isoforms — 111
6.2.3	Reference range — 114
6.3	Chemical pathology — 114
6.3.1	Heart disease — 114
6.3.2	Skeletal muscle disease — 116
6.3.3	Trauma — 116
6.4	Analytical measurement of total CK and CK-MB — 117
6.5	Questions and answers — 118
	References — 119
7	Gamma-glutamyl transferase — 121
	Sarah M. Brown
7.1	Case studies — 121
7.1.1	Patient A — 121
7.1.2	Patient B — 121
7.1.3	Patient C — 122
7.1.4	Patient D — 123
7.1.5	Patient E — 124
7.2	Biochemistry and physiology — 124
7.2.1	Molecular forms and post-translational modification — 124
7.2.2	Biochemical function — 125
7.2.3	Tissue activities and concentrations — 125
7.2.4	Metabolic clearance — 126
7.2.5	Reference intervals — 126

- 7.3 Chemical pathology — 126
- 7.3.1 Causes of increased or decreased concentrations or activities — 126
- 7.3.2 Diagnostic utility of GGT — 127
- 7.4 Analysis — 131
- 7.4.1 Specimen and stability — 131
- 7.4.2 Preferred method for GGT activity — 131
- 7.5 Questions and answers — 132
- References 132

8 Lactate dehydrogenase — 135

Olajumoke Oladipo and Dennis J. Dietzen

- 9.1 Case studies — 135
- 8.1.1 Patient A — 135
- 8.1.2 Patient B — 136
- 8.1.3 Patient C — 137
- 8.1.4 Patient D — 138
- 8.1.5 Patient E — 139
- 8.2 Biochemistry and physiology — 140
- 8.2.1 Physiological function — 140
- 8.2.2 Tissue sources — 140
- 8.2.3 Reference ranges — 141
- 8.3 Chemical pathology — 141
- 8.3.1 Cardiology — 142
- 8.3.2 Hepatology — 142
- 8.3.3 Hematology — 142
- 8.3.4 Oncology — 143
- 8.3.5 Neurology — 143
- 8.3.6 Macro-LD — 144
- 8.3.7 Genetic deficiencies — 144
- 8.4 Analysis — 144
- 8.4.1 LD isoenzyme determination — 145
- 8.4.2 IFCC reference method — 145
- 8.4.3 Specimen — 146
- 8.5 Questions and answers — 146
- References — 147

9 Pancreatic lipase — 153

Wan-Ming Zhang, Edmunds Reineks, Joe M. El-Khoury and Sihe Wang

- 9.1 Case studies — 153
- 9.1.1 Patient A — 153
- 9.1.2 Patient B — 154

9.1.3	Patient C — 155
9.1.4	Patient D — 156
9.2	Biochemistry and physiology — 157
9.2.1	Molecular forms — 157
9.2.2	Molecular structure and tissue expression — 158
9.2.3	Mechanism of catalysis — 159
9.2.4	Functional regulation — 159
9.2.5	Lipase in serum — 161
9.2.6	Other lipases — 162
9.2.7	Reference range and standardization — 164
9.3	Chemical pathology — 164
9.3.1	Acute pancreatitis — 164
9.3.2	Pancreatic cancer — 165
9.3.3	Cystic fibrosis — 166
9.3.4	Diabetic ketoacidosis — 166
9.3.5	Chronic renal failure — 167
9.3.6	Iatrogenic effects — 167
9.3.7	Drug effects — 167
9.4	Analysis — 168
9.4.1	Specimen — 168
9.4.2	Methods and instrumentation — 168
9.5	Questions and answers — 171
	References — 172

10 Natriuretic peptides — 181

Robert H. Christenson and Hassan M.E. Azzazy

10.1	Case studies — 181
10.1.1	Patient A — 181
10.1.2	Patient B — 182
10.1.3	Patient C — 182
10.1.4	Patient D — 183
10.1.5	Patient E — 184
10.1.6	Patient F — 185
10.2	Biochemistry and physiology of cardiac natriuretic peptides — 185
10.3	Chemical pathology of natriuretic peptides — 186
10.3.1	BNP in diagnosis of symptomatic HF patients — 187
10.3.2	Prognosis and risk stratification of HF patients — 187
10.3.3	BNP and NT-proBNP as prognostic risk markers in acute coronary syndrome patients — 188
10.3.4	Recommendations for use of Biochemical markers in heart failure — 188

10.4	Analytical measurements of BNP and NT-proBNP —	188
10.4.1	Desired specimens —	188
10.4.2	Considerations for measurements of BNP and NT-proBNP —	189
10.4.3	Methods for measurements —	190
10.5	Questions and answers —	191
	References —	192

Index —	195
----------------	------------